WuXi Biologics: The main structure of the module-based biologics manufacturing plant in the Singapore CRDMO Center has been topped off.

WuXi Biologics announced that it has completed the main structure topping-out of its modular biopharmaceutical manufacturing facility in Singapore, CRDMO center. The facility is designed and constructed according to the latest and strictest international standards in the market, and once completed, it will become the company's core drug manufacturing base. It is expected to produce approximately 100 million pre-filled syringes and vials of insulin annually.